Immune Design Corp (NASDAQ:IMDZ) EVP Stephen R. Brady sold 3,328 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.17, for a total value of $13,877.76. Following the completion of the transaction, the executive vice president now owns 50,490 shares of the company’s stock, valued at approximately $210,543.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Immune Design Corp (NASDAQ:IMDZ) traded down $0.15 during trading hours on Thursday, hitting $3.25. The stock had a trading volume of 675,239 shares, compared to its average volume of 629,365. Immune Design Corp has a 1 year low of $3.15 and a 1 year high of $13.05. The company has a market capitalization of $156.19, a P/E ratio of -1.53 and a beta of 2.36.
Immune Design (NASDAQ:IMDZ) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.11. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.62 million. sell-side analysts anticipate that Immune Design Corp will post -1.89 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its position in shares of Immune Design by 9.3% during the second quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 1,600 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Immune Design by 8.3% during the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 2,300 shares during the last quarter. Teachers Advisors LLC boosted its position in shares of Immune Design by 23.0% during the second quarter. Teachers Advisors LLC now owns 27,691 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 5,181 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Immune Design by 53.9% during the second quarter. Rhumbline Advisers now owns 19,694 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 6,896 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in shares of Immune Design by 95.1% during the second quarter. New York State Common Retirement Fund now owns 20,100 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 9,799 shares during the last quarter. 29.38% of the stock is currently owned by institutional investors.
A number of equities analysts have issued reports on the company. ValuEngine downgraded Immune Design from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Wells Fargo & Co downgraded Immune Design from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. Cowen restated a “buy” rating on shares of Immune Design in a report on Monday, December 11th. Finally, Zacks Investment Research downgraded Immune Design from a “buy” rating to a “hold” rating in a report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $13.06.
TRADEMARK VIOLATION WARNING: “Immune Design Corp (IMDZ) EVP Sells $13,877.76 in Stock” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/01/stephen-r-brady-sells-3328-shares-of-immune-design-corp-imdz-stock.html.
Immune Design Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.